Complication and Pain Comparison of 2 Brands of Botolinum Toxin A, Diluted with Lidocaine vs Normal Saline

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210401050804N1

Enrollment

Registered

2021-04-26

Start date

2021-04-25

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial aging.

Interventions

Intervention 1: Control group: Group A: 100 mg Botolinum Toxin manufactured by Ipsen sold under the trade name Dysport, mixed with 1 ml Normal Saline without preservative. Intervention 2: Interventio

100 mg Botolinum Toxin manufactured by Ipsen sold under the trade name Dysport, mixed with 1 ml Lidocaine 2%. Intervention 3: Intervention group No. 2: Group C

100 mg Botolinum Toxin manufactured by Merz sold under the trade name Xeomin, mixed with 1 ml Normal Saline without preservative.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients without any Systemic disease

Exclusion criteria

Exclusion criteria: Patients who have experienced unpleasant injection will be eliminated from the study Patients who are allergic to Botulinum Toxin

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Pain during injection. Method of measurement: Patient will rate their pain according to Visual Analogue Scale wherein highest tolerable pain is rated 10 (0 to 3 means mild pain; 4 to 6 is considered moderate pain; 7 to 10 is severe pain).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDiba Bagheri

Islamic Azad University

diba.bgi@gmail.com+98 21 2212 1467

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026